{
    "2019-05-20": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Top Analyst Reports for Johnson & Johnson, Apple & Goldman Sachs",
                "features": {
                    "keywords": [
                        "analyst reports",
                        "Johnson & Johnson",
                        "Apple",
                        "Goldman Sachs"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "technology",
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-05-20",
                "original_text": "ARWR: ARO-AAT Ph 2/3 Detailed, Could Serve as FDA Pivotal Study. Continued Broad-Based Pipeline Progress",
                "features": {
                    "keywords": [
                        "ARWR",
                        "ARO-AAT",
                        "FDA",
                        "pivotal study",
                        "pipeline progress"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-20",
                "original_text": "Drugmakersâ€™ lobbying spending at 10-year high as Washington targets soaring prices",
                "features": {
                    "keywords": [
                        "drugmakers",
                        "lobbying",
                        "spending",
                        "Washington",
                        "prices"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-05-20",
                "original_text": "AbbVie's Brain Cancer Candidate Fails in Phase III Study",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "brain cancer",
                        "Phase III",
                        "study failure"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-05-20",
                "original_text": "This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "dividend stock"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-20",
                "original_text": "Health Care Sector Update for 05/20/2019: MDCO, QGEN, INNT, JNJ, PFE, ABT, MRK, AMGN",
                "features": {
                    "keywords": [
                        "health care sector",
                        "MDCO",
                        "QGEN",
                        "INNT",
                        "JNJ",
                        "PFE",
                        "ABT",
                        "MRK",
                        "AMGN"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-20",
                "original_text": "After J&J sale, Cambridge investor sets sights on $175M raise for new medtech VC firm",
                "features": {
                    "keywords": [
                        "J&J sale",
                        "Cambridge investor",
                        "medtech",
                        "VC firm"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "venture capital"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}